File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of naringin on bone cells

TitleEffect of naringin on bone cells
Authors
KeywordsBone cell
HMG-CoA reductase inhibitor
Naringin
Issue Date2006
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.elsevier.com/locate/orthres
Citation
Journal Of Orthopaedic Research, 2006, v. 24 n. 11, p. 2045-2050 How to Cite?
AbstractStatin, a HMG-CoA reductase inhibitor, was shown to increase BMIP-2 gene expression for bone formation, by blocking the mevalonate pathway in cholesterol production. We investigated the effect of naringin, a flavonoid available commonly in citrus fruits, which was also a HMG-CoA reductase inhibitor, in UMR 106 osteoblastic cell line in vitro. The control group consisted of cells cultured without any intervention for different time intervals (24 h, 48 h, and 72 h), whereas the experimental (naringin) group consisted of cells cultured with naringin of different concentrations (0.001 μmol/L, 0.01 μmol/L, and 0.1 μmol/L) for the same time intervals of the control. Colorimetric Tetrazolium. (MTT) assay, total protein content assay, and alkaline phosphatase activity were used to measure the cellular activities. Results for the naringin group showed an increase in MTT assay compared with the control and the effect was dose dependent. At high concentration (0. 1 μmol), the increases ranged from 60% to 80%. In the total protein content assay, naringin also showed an increase compared with control and the effect was also dose dependent. At high concentration (0.1 μmol), the increases ranged from 9% to 20%. In the alkaline phosphatase activity assay, naringin at high concentration (0.1 μmol) significantly increased the activity up to 20%. In conclusion, naringin significantly increased bone cell activities in vitro. This is the first study specifically attempted to investigate the effect of naringin on bone cell activities. Besides statin, this provided another example of mevalonate pathway blockage in the cholesterol production pathway by HMG-CoA reductase inhibition will increase the bone cell activities. © 2006 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/67037
ISSN
2015 Impact Factor: 2.807
2015 SCImago Journal Rankings: 1.464
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, RWKen_HK
dc.contributor.authorRabie, ABMen_HK
dc.date.accessioned2010-09-06T05:51:26Z-
dc.date.available2010-09-06T05:51:26Z-
dc.date.issued2006en_HK
dc.identifier.citationJournal Of Orthopaedic Research, 2006, v. 24 n. 11, p. 2045-2050en_HK
dc.identifier.issn0736-0266en_HK
dc.identifier.urihttp://hdl.handle.net/10722/67037-
dc.description.abstractStatin, a HMG-CoA reductase inhibitor, was shown to increase BMIP-2 gene expression for bone formation, by blocking the mevalonate pathway in cholesterol production. We investigated the effect of naringin, a flavonoid available commonly in citrus fruits, which was also a HMG-CoA reductase inhibitor, in UMR 106 osteoblastic cell line in vitro. The control group consisted of cells cultured without any intervention for different time intervals (24 h, 48 h, and 72 h), whereas the experimental (naringin) group consisted of cells cultured with naringin of different concentrations (0.001 μmol/L, 0.01 μmol/L, and 0.1 μmol/L) for the same time intervals of the control. Colorimetric Tetrazolium. (MTT) assay, total protein content assay, and alkaline phosphatase activity were used to measure the cellular activities. Results for the naringin group showed an increase in MTT assay compared with the control and the effect was dose dependent. At high concentration (0. 1 μmol), the increases ranged from 60% to 80%. In the total protein content assay, naringin also showed an increase compared with control and the effect was also dose dependent. At high concentration (0.1 μmol), the increases ranged from 9% to 20%. In the alkaline phosphatase activity assay, naringin at high concentration (0.1 μmol) significantly increased the activity up to 20%. In conclusion, naringin significantly increased bone cell activities in vitro. This is the first study specifically attempted to investigate the effect of naringin on bone cell activities. Besides statin, this provided another example of mevalonate pathway blockage in the cholesterol production pathway by HMG-CoA reductase inhibition will increase the bone cell activities. © 2006 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.elsevier.com/locate/orthresen_HK
dc.relation.ispartofJournal of Orthopaedic Researchen_HK
dc.rightsJournal of Orthopaedic Research. Copyright © John Wiley & Sons, Inc.en_HK
dc.subjectBone cellen_HK
dc.subjectHMG-CoA reductase inhibitoren_HK
dc.subjectNaringinen_HK
dc.subject.meshAlkaline Phosphatase - metabolismen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshCell Line, Tumoren_HK
dc.subject.meshCell Survival - drug effectsen_HK
dc.subject.meshDose-Response Relationship, Drugen_HK
dc.subject.meshFlavanones - pharmacologyen_HK
dc.subject.meshFormazans - metabolismen_HK
dc.subject.meshHydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacologyen_HK
dc.subject.meshOsteoblasts - drug effects - metabolismen_HK
dc.subject.meshOsteosarcomaen_HK
dc.subject.meshProteins - metabolismen_HK
dc.subject.meshRatsen_HK
dc.subject.meshTetrazolium Salts - metabolismen_HK
dc.titleEffect of naringin on bone cellsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0736-0266&volume=24&spage=2045&epage=2050&date=2006&atitle=Effect+of+Naringin+on+Bone+Cellsen_HK
dc.identifier.emailWong, RWK: fyoung@hku.hken_HK
dc.identifier.emailRabie, ABM: rabie@hku.hken_HK
dc.identifier.authorityWong, RWK=rp00038en_HK
dc.identifier.authorityRabie, ABM=rp00029en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/jor.20279en_HK
dc.identifier.pmid16944474-
dc.identifier.scopuseid_2-s2.0-33750872026en_HK
dc.identifier.hkuros119871en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33750872026&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume24en_HK
dc.identifier.issue11en_HK
dc.identifier.spage2045en_HK
dc.identifier.epage2050en_HK
dc.identifier.eissn1554-527X-
dc.identifier.isiWOS:000241573600003-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWong, RWK=7402127170en_HK
dc.identifier.scopusauthoridRabie, ABM=7007172734en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats